This short video presentation outlines the diagnosis and assessment of COPD according to the 2024 GOLD report, focusing on clinical features and assessment goals.
This short video presentation outlines the diagnosis and assessment of COPD according to the 2024 GOLD report, focusing on clinical features and assessment goals.
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Pulmonology
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
Pulmonology
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology
Pulmonology
Join Klaus Rabe, MD, PhD, Stephanie Christenson, MD, PhD, and Dave Singh, MD, FERS, FBPhS as they discuss the relationship between clinical presentation and disease pathology, unravel the diverse inflammatory pathways driving COPD's heterogeneity, and review the evolving clinical landscape.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.